EUVIMEDEUVIMED entdecken
Crossref

Targeting virulence of resistant Escherichia coli by the FDA-approved drugs sitagliptin and nitazoxanide as an alternative antimicrobial approach

Sara M Eltabey, Ali H Ibrahim, Mahmoud M Zaky, Adel Ehab Ibrahim, Yahya Bin Abdullah Alrashdi, Sami El Deeb, Moustafa M Saleh

Folia Microbiologica · 2025

DOI: 10.1007/s12223-024-01215-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Folia Microbiologica, 2025. Verfasst von Sara M Eltabey und 6 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology Program, Botany Department, Faculty of Science, Port Said University, Port Said, Egypt. Hauptthemen laut MEDLINE: Escherichia coli, Sitagliptin Phosphate, Thiazoles, Escherichia coli Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The spread of multidrug-resistant Escherichia coli in healthcare facilities is a global challenge. Hospital-acquired infections produced by Escherichia coli include gastrointestinal, blood-borne, urinary tract, surgical sites, and neonatal infections. Therefore, novel approaches are needed to deal with this pathogen and its rising resistance. The concept of attenuating virulence factors is an alternative strategy that might lead to low levels of resistance and combat this pathogen. A sub-inhibitory concentration (¼ MIC) of sitagliptin and nitazoxanide was used for phenotypic assessments of Escherichia coli virulence factors such as biofilm production, swimming motility, serum resistance, and protease production. Moreover, qRT-PCR was used to determine the impact of sub-MIC of the tested drugs on the relative expression levels of papC, fimH, fliC, kpsMTII, ompT_m, and stcE genes encoding virulence factors in Escherichia coli. Also, an in vivo model was conducted as a confirmatory test. Phenotypically, our findings demonstrated that the tested strains showed a significant decrease in all the tested virulence factors. Moreover, the genotypic results showed a significant downregulation in the relative expression levels of all the tested genes. Besides, the examined drugs were found to be effective in protecting mice against Escherichia coli pathogenesis. Sitagliptin and nitazoxanide exhibited strong anti-virulence activities against Escherichia coli. In addition, it is recommended that they might function as adjuvant in the management of Escherichia coli infections with either conventional antimicrobial agents or alone as alternative treatment measures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Escherichia coliSitagliptin PhosphateThiazolesEscherichia coli InfectionsAnti-Bacterial AgentsAnimalsMiceVirulence FactorsVirulenceMicrobial Sensitivity TestsNitro CompoundsBiofilmsHumansEscherichia coli ProteinsFemaleDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

Escherichia coliAntibiotic resistanceNitazoxanideSitagliptinVirulence inhibitors

Substanzen

nitazoxanideSitagliptin PhosphateThiazolesVirulence FactorsNitro CompoundsAnti-Bacterial AgentsEscherichia coli Proteins

Autor:innen und Institutionen

  • Microbiology Program, Botany Department, Faculty of Science, Port Said University, Port Said, Egypt.
  • Botany Department, Faculty of Science, Port Said University, Port Said, Egypt.
  • Natural and Medical Sciences Research Center, University of Nizwa, Birkat Al Mauz, P.O. Box 33, Nizwa, 616, Oman. adel@unizwa.edu.om.
  • College of Pharmacy and Nursing, University of Nizwa, Birkat Al Mauz, Nizwa, 616, Oman.
  • Institute of Medicinal and Pharmaceutical Chemistry, Technische Universitaet Braunschweig, Brunswick, Germany. s.eldeeb@tu-bs.de.
  • Microbiology and Immunology Department, Faculty of Pharmacy, Port Said University, Port Said, Egypt.

Zitieren

APA

Eltabey, S. M., Ibrahim, A. H., Zaky, M. M., Ibrahim, A. E., Alrashdi, Y. B. A., El Deeb, S., & Saleh, M. M. (2025). Targeting virulence of resistant Escherichia coli by the FDA-approved drugs sitagliptin and nitazoxanide as an alternative antimicrobial approach. Folia Microbiologica. https://doi.org/10.1007/s12223-024-01215-7

Vancouver

Eltabey SM, Ibrahim AH, Zaky MM, Ibrahim AE, Alrashdi YBA, El Deeb S, et al. Targeting virulence of resistant Escherichia coli by the FDA-approved drugs sitagliptin and nitazoxanide as an alternative antimicrobial approach. Folia Microbiologica. 2025. doi:10.1007/s12223-024-01215-7

BibTeX
@article{Eltabey2025,
  author = {Eltabey, Sara M and Ibrahim, Ali H and Zaky, Mahmoud M and Ibrahim, Adel Ehab and Alrashdi, Yahya Bin Abdullah and El Deeb, Sami and Saleh, Moustafa M},
  title = {Targeting virulence of resistant Escherichia coli by the FDA-approved drugs sitagliptin and nitazoxanide as an alternative antimicrobial approach},
  journal = {Folia Microbiologica},
  year = {2025},
  doi = {10.1007/s12223-024-01215-7}
}
Kostenlos starten →